The Biological Basis of Hodgkin's Lymphoma

Drug News and Perspectives

Volumn 16, Issue 10, 2003, Pages 649-656

  Horie, Ryouichi ^a,b   Watanabe, Toshiki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD30 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL PROTEIN; CYCLIN D2; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 13; LATENT MEMBRANE PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL XL; STAT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; GENE EXPRESSION; GENE MUTATION; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE C JUN; PATHOPHYSIOLOGY; REED STERNBERG CELL; REVIEW;

ANIMALS; ANTIGENS, CD30; CELL SURVIVAL; HODGKIN DISEASE; HUMANS; NF-KAPPA B; REED-STERNBERG CELLS;

EID: 1042302012     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.10.829295     Document Type: Review

References (46)

1. Hodgkin, T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832, 17: 68-114.
2. Kaufman, D. and Longo, D.L. Hodgkin's disease. Crit Rev Oncol Hematol 1992, 13: 135-87.
3. Gruss, H.J. and Kadin, M.E. Pathophysiology of Hodgkin's disease: Functional and molecular aspects. Baillieres Clin Haematol 1996, 9: 417-46.
4. Kanzler, H., Kuppers, R., Hansmann, M.L. and Rajewsky, K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996, 184: 1495-505.
5. Cossman, J., Annunziata, C.M., Barash, S. et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999, 94: 411-6.
6. Kuppers, R. and Rajewsky, K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998, 16: 471-93.
7. Stein, H. and Hummel, M. Cellular origin and clonality of classic Hodgkin's lymphoma: Immunophenotypic and molecular studies. Semin Hematol 1999, 36: 233-41.
8. Bargou, R.C., Leng, C., Krappmann, D. et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87: 4340-7.
9. Bargou, R.C., Enmaerich, F., Krappmann, D. et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997, 100: 2961-9.
10. Ghosh, S., May, M.J. and Kopp, E.B. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16: 225-60.
11. Chen, F.E. and Ghosh, G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: Structural views. Oncogene 1999, 18: 6845-52.
12. Pahl, H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18: 6853-66.
13. Hinz, M., Loser, P., Mathas, S., Krappmann, D., Dorken, B. and Scheidereit, C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001, 97: 2798-807.
14. Hinz, M., Lemke, P., Anagnostopoulos, I. et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002, 196: 605-17.
15. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107: 241-6.
16. Cabannes, E., Khan, G., Aillet, F., Jarrett, R.F. and Hay, R.T. Mutations in the IkBa gene in Hodgkin's disease suggest a rumour suppressor role for IkappaBalpha. Oncogene 1999, 18: 3063-70.
17. Jungnickel, B., Staratschek-Jox, A., Brauninger, A. et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000, 191: 395-402.
18. Emmerich, F., Meiser, M., Hummel, M. et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999, 94: 3129-34.
19. Wood, K.M., Roff, M. and Hay, R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 1998, 16: 2131-9.
20. Fiumara, P., Snell, V., Li, Y. et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001, 98: 2784-90.
21. Horie, R., Watanabe, T., Morishita, Y. et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21: 2493-503.
22. Staratschek-Jox, A., Kotkowski, S., Belge, G. et al. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: No evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease. Am J Pathol 2000, 156: 209-16.
23. Gires, O., Zimber-Strobl, U., Gonnella, R. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997, 16: 6131-40.
24. Izumi, K.M. and Kieff, E.D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997, 94: 12592-7.
25. Kim, S.H., Shin, Y.K., Lee, I.S. et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 2000, 95: 294-300.
26. Knecht, H., McQuain, C., Martin, J. et al. Expression of the LMP1 oncoprotein in the Epstein-Barr virus negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene 1996, 13: 947-53.
27. Teramoto, N., Cao, L., Kawasaki, N. et al. Variable expression of Epstein-Barr virus latent membrane protein I in Reed-Sternberg cells of Hodgkin's disease. Acta Med Okayama 1996, 50: 267-70.
28. Maniatis, T. Catalysis by a multiprotein IkappaB kinase complex. Science 1997, 278: 818-9.
29. Schwab, U., Stein, H., Gerdes, J. et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299: 65-7.
30. Stein, H., Gerdes, J., Schwab, U. et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer 1982, 30: 445-59.
31. Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. and Stein, H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68: 421-7.
32. Smith, C.A., Gruss, H.J., Davis, T. et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73: 1349-60.
33. Izban, K.F., Ergin, M., Martinez, R.L. and Alkan, S. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol 2000, 13: 1324-31.
34. Durkop, H., Foss, H.D., Demel, G., Klotzbach, H., Hahn, C. and Stein, H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 1999, 93: 617-23.
35. Zapata, J.M., Krajewska, M., Krajewski, S. et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000, 165: 5084-96.
36. Horie, R., Watanabe, T., Ito, K. et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 2002, 160: 1647-54.
37. Croager, E.J., Muir, T.M. and Abraham, L.J. Analysis of the human and mouse promoter region of the non-Hodgkin's lymphoma-associated CD30 gene. J Interferon Cytokine Res 1998, 18: 915-20.
38. Croager, E.J., Gout, A.M. and Abraham, L.J. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000, 156: 1723-31.
39. Durkop, H., Oberbarnscheidt, M., Latza, U. et al. The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter. J Pathol 2000, 192: 182-93.
40. Durkop, H., Oberbarnscheidt, M., Latza, U. et al. Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30(+) cell lines. Biochim Biophys Acta 2001, 1519: 185-91.
41. Kadin, M.E. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000, 156: 1479-84.
42. Watanabe, M., Ogawa, Y., Ito, K. et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 2003, 163: 633-41.
43. Mathas, S., Hinz, M., Anagnostopoulos, I. et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002, 21: 4104-13.
44. Schorpp-Kistner, M., Wang, Z.Q., Angel, P. and Wagner, E.F. JunB is essential for mammalian placentation. EMBO J 1999, 18: 934-48.
45. Passegue, E., Jochum, W., Behrens, A., Ricci, R. and Wagner, E.F. JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet 2002, 30: 158-66.
46. Robinson, C.M., Prime, S.S., Huntley, S. et al. Overexpression of JunB in undifferentiated malignant rat oral keratinocytes enhances the malignant phenotype in vitro without altering cellular differentiation. Int J Cancer 2001, 91: 625-30.